Logo

American Heart Association

  18
  0


Final ID: MP193

Impact of Global Longitudinal Strain on Event-Free Survival Time of Patients with Heart Failure

Abstract Body (Do not enter title and authors here): Introduction: Left ventricular global longitudinal strain (GLS) is a known independent predictor of mortality and hospitalization in heart failure (HF). Nonetheless, the impact of GLS on the event-free survival time remains unclear. Hypothesis: We hypothesize an improvement of GLS is associated with an increase in the event-free survival of patients with HF. Method: A single center, retrospective, cohort, observational study was conducted among consecutive patients with HF from all spectra of ejection fraction, with at least two echocardiograms: one on admission and another one at follow-up encounter. Subjects were identified from the pool of echocardiograms performed between October 2023 and April 2024 in the New York Metropolitan Hospital. Cases with atrial fibrillation, hemodialysis and poor echocardiogram images were excluded. Electronic medical records were reviewed from October 2023 to March 2025; The GLS from the penultimate (GLS1) and latest echocardiogram (GLS2) were assessed by 2-dimensional speckle-tracking software and were converted to absolute GLS for presentation purposes. Patients were divided according to the median GLS2 into two groups: above and below 11.35. Primary outcome was time to first occurrence of HF hospitalization or cardiovascular death. Results: Out of 325 subjects, 63 met inclusion criteria for the final analysis. Mean follow-up interval was 415 ± 41 days. Mean interval between echocardiograms was 374 ± 34 days. Median GLS of the penultimate and last echocardiogram were 12.00 and 11.35, respectively. Patients with higher GLS2 correlated with longer event-free survival time, 95% CI (0.13 – 0.60), df=62; p=0.039. When analyzing continuous variables (df=62), every 1 unit increment of GLS, the event-free survival time increased by 12 ±2.2 days, CI=95%; p=0.037. Those with GLS2≧11.35 showed longer event-free survival according to the Kaplan Meier Curve: Chi Sq (Breslow, and Tarone-Ware methods) = 8.470 (df=1); 95 % CI; p=0.005. Conclusion: Improvement of GLS is associated with an increase in the event-free survival of patients with HF. For every 1-unit increment of GLS, the event-free survival time will increase by 12 days.
  • Hung, Chien Yang  ( New York Medical College Metropolitan Hospital , NEW YORK CITY , New York , United States )
  • Neupane, Sandhya  ( New York Medical College Metropolitan Hospital , NEW YORK CITY , New York , United States )
  • Nriagu, Bede  ( New York Medical College Metropolitan Hospital , NEW YORK CITY , New York , United States )
  • Charpuria, Poornima J  ( New York Medical College Metropolitan Hospital , NEW YORK CITY , New York , United States )
  • Altonen, Brian  ( New York City Health and Hospital Corporation , New York , New York , United States )
  • Zuniga, Diego  ( New York Medical College Metropolitan Hospital , NEW YORK CITY , New York , United States )
  • Gebran, Karim  ( New York Medical College Metropolitan Hospital , NEW YORK CITY , New York , United States )
  • Mushiyev, Savi  ( New York Medical College Metropolitan Hospital , NEW YORK CITY , New York , United States )
  • Abascal, Vivian  ( Mount Sinai Fuster Heart Hospital , New York , New York , United States )
  • Moreno, Pedro  ( Mount Sinai Fuster Heart Hospital , New York , New York , United States )
  • Pathakamudi, Poojitha  ( New York Medical College Metropolitan Hospital , NEW YORK CITY , New York , United States )
  • Gonzalez B, Oscarina  ( New York Medical College Metropolitan Hospital , NEW YORK CITY , New York , United States )
  • Author Disclosures:
    Chien Yang Hung: DO NOT have relevant financial relationships | Sandhya Neupane: No Answer | Bede Nriagu: DO NOT have relevant financial relationships | Poornima J Charpuria: No Answer | Brian Altonen: No Answer | Diego Zuniga: No Answer | Karim Gebran: No Answer | Savi Mushiyev: No Answer | Vivian Abascal: DO NOT have relevant financial relationships | Pedro Moreno: No Answer | Poojitha Pathakamudi: No Answer | Oscarina Gonzalez B: No Answer
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Heart Failure and Cardiomyopathies: Management

Saturday, 11/08/2025 , 01:45PM - 03:00PM

Moderated Digital Poster Session

More abstracts on this topic:
Effects of Sacubitril-Valsartan on Prevention of Cardiotoxicity in High-Risk Patients Undergoing Anthracycline Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial – The SARAH Trial

Bonatto Marcely, Zaninelli Maiolino Julyana, Mosko Larissa Arlete, Mialski Talita, Ota Tammy, Moura Lidia, Cauduro Sanderson, Bocchi Edimar, Ferreira Silvia, Avila Monica, Lechinewski Luka, Torres Rafael, Costa Amanda, Coiradas Andressa, Costa Nadya, Contin Lais

Ability of Composite Magnetic Resonance Brain Imaging Scores to Predict Functional Outcomes in Survivors of Cardiac Arrest

Nguyen Thuhien, Town James, Wahlster Sarah, Johnson Nicholas, Poilvert Nicolas, Lin Victor, Ukatu Hope, Matin Nassim, Davis Arielle, Taylor Breana, Thomas Penelope, Sharma Monisha

More abstracts from these authors:
Case #3 Hard as a Rock-Case of a severely calcified lesion

Gonzalez Carlos, Moreno Pedro

SOTA-P-CARDIA Trial (ATRU-V). A Randomized Trial of Sotagliflozin in HFpEF patients without diabetes.

Badimon Juan, Lam David, Abascal Vivian, Lerakis Stamatios, Mancini Donna, Sartori Samantha, Requena Juan Antonio, Santos-gallego Carlos, Ferrandez Marcos, Zafar Mohammad, Angermann Christiane, Fuster Valentin, Lajam Farah, Fergus Icilma

You have to be authorized to contact abstract author. Please, Login
Not Available